Departmental Unit of Allergology, Clinical Immunology and Respiratory Diseases, Istituto Ospedaliero Fondazione Poliambulanza, Brescia.
Department of Internal Medicine, Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, Genoa, Italy.
Curr Opin Allergy Clin Immunol. 2020 Aug;20(4):421-427. doi: 10.1097/ACI.0000000000000656.
New biological agents, in addition to the well-established omalizumab, have been nowadays introduced into clinical practice for severe asthma. This suggested the possibility of an at-home self-administration, as currently happening for other biological agents for immune-mediated diseases.
In the very recent years, there were structured clinical trials investigating the self at home administrations of biologicals for severe asthma, showing with different principles, a possible advantage and convenience for the patient, and a socioeconomic saving.
The literature analysis currently shows that the at-home self-administration of biologicals for severe asthma is a promising approach to improve the treatment of such disease.
除了已被广泛应用的奥马珠单抗以外，目前还有一些新的生物制剂被应用于严重哮喘的临床治疗。这提示我们，生物制剂的居家自我给药治疗可能会成为现实，就像目前其他免疫介导性疾病的生物制剂一样。
在最近的几年中，已经有一些针对严重哮喘的生物制剂居家自我给药治疗的临床试验，这些研究结果显示，不同的给药原则可能会给患者带来更多的便利和优势，同时也能节省社会经济成本。
目前的文献分析表明，严重哮喘的生物制剂居家自我给药治疗是一种很有前途的治疗方法，可以改善此类疾病的治疗效果。
